Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire buys repurposed Pfizer/Sanofi drugs through $260m Lumena acquisition

This article was originally published in Scrip

Executive Summary

Shire has acquired rare disease-focused Lumena Pharmaceuticals of San Diego for $260m in cash. Lumena is developing repurposed cholesterol-lowering drugs that it licensed from Pfizer and Sanofi to treat cholestatic liver diseases. A further payment for the biotech's cash on closing and milestone payments related to ongoing clinical trials are also included in the deal.

Advertisement

Related Content

Reneo Reveals $50m Series A, Mitochondrial Disease Development Plans
Newly Hatched Mirum To Focus On Rare Liver Disease Candidates Shelved By Shire
Workforce Roundtable Part 3: Diversity And Progress – And Advice For Biopharma's Next Generation
Workforce Roundtable Part 2: Creating A 'Sticky' Workplace, Boardroom Roles For Women, Millennials
Workforce Roundtable Part 1: Recruiting Biopharma Leaders As The Talent Pool Shrinks And Diversifies
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025276

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel